We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of ...

Under Strategic Platform License (SPL) agreements, the company worked with Vertex Pharmaceuticals and CRISPR Therapeutics ... Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

The company's flagship treatment, Casgevy, developed in partnership with Vertex Pharmaceuticals, has received regulatory ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

According to the study, activity on Instagram, LinkedIn, YouTube and X (formerly Twitter) are the most important platforms ...